Core Viewpoint - The stock of Kaidi Co., Ltd. has seen a significant increase of 6.00% on November 21, with a trading volume of 353 million yuan and a market capitalization of 6.541 billion yuan [1] Group 1: Company Overview - Kaidi Co., Ltd. is a leading manufacturer of automotive components in China, focusing on high-quality products for both traditional and new energy vehicles [2] - The company has a strong presence in the photovoltaic sector, with customized linear drive structures for solar support frames, although sales revenue from solar projects has not yet been realized [2][3] - The company’s smart medical division offers a range of medical equipment, including medical beds and electric wheelchairs, aiming to become a globally recognized manufacturer in the smart medical device sector [3] - The smart home division emphasizes innovation in product development, covering smart furniture and integrated home automation systems [3] Group 2: Financial Performance - For the period ending September 2025, Kaidi Co., Ltd. reported a revenue of 926 million yuan, reflecting a year-on-year growth of 3.67%, while net profit attributable to shareholders decreased by 59.64% to 28.69 million yuan [7] - The company has a significant overseas revenue contribution, accounting for 56.46% of total revenue, benefiting from the depreciation of the Chinese yuan [3] Group 3: Shareholder and Market Activity - As of November 10, 2025, the number of shareholders decreased by 23.09% to 5,298, while the average number of shares held per shareholder increased by 30.03% to 13,250 shares [7] - The stock has seen a net inflow of 28.4 million yuan from major investors, indicating a positive sentiment towards the stock despite a broader industry outflow of 1.526 billion yuan [4][5]

Core Viewpoint - The company, Haiprui, experienced a decline of 4.14% in stock price, with a trading volume of 53.28 million yuan and a total market capitalization of 16.977 billion yuan [1] Group 1: Company Overview - Haiprui, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][3] - The main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7] Group 2: Financial Performance - For the period from January to September 2025, Haiprui achieved operating revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to the parent company was 554 million yuan, a decrease of 29.04% year-on-year [7] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with cumulative distributions of 514 million yuan over the past three years [8] Group 3: Market Position and Trends - As of the 2024 annual report, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the yuan [3] - The company is involved in the mRNA vaccine development and production CDMO services through its subsidiary, Saiwan Bio, which supports the supply chain for multiple commercialized mRNA vaccines [2]

来源：新浪证券-红岸工作室 11月20日，开创电气跌3.68%，成交额5906.22万元，换手率2.14%，总市值58.94亿元。 异动分析 锂电池概念+人民币贬值受益+专精特新+跨境电商 1、据2024年5月8日互动易：2023 年公司开发锂电新产品 20 款，受到博世、Harbor Freight Tools 等客户 的认可。公司目前锂电产品的销售占比，不到总销售收入的 10%，还有很大的提升空间。谢谢！ 2、根据2024年年报，公司海外营收占比为91.85%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 4、根据2025年7月4日互动易：公司于2018年开始布局电商业务。先后在金华、杭州、深圳成立跨境电 商公司，通过亚马逊及其他电商平台推广及销售公司自主品牌电动工具及其他品类产品。2024年公司线 上销售收入同比增长58.64%。 ...

来源：新浪证券-红岸工作室 11月20日，捷邦科技跌0.52%，成交额7862.59万元，换手率2.73%，总市值76.80亿元。 异动分析 液冷服务器+富士康概念+苹果概念+锂电池概念+人民币贬值受益 1、根据2025年7月17日互动易：目前公司服务器液冷散热业务按计划正常推进中。但由于公司与客户签 署了保密协议，目前暂时无法提供具体的项目细节。 5、根据2024年年报，公司海外营收占比为67.79%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入157.52万，占比0.02%，行业排名22/98，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入-6.23亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入157.52万366.14万420.67万-4602.07万-1.03亿 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额2842.57万，占总成交额的4.44%。 技术面：筹码平均交易成本为122.28元 2、公司直接客户主要为富士康、广达集团、仁宝电脑、可成科技、比亚迪等苹果组件生 ...

Core Viewpoint - The company, Wuhan LianTe Technology Co., Ltd., is experiencing fluctuations in stock performance, with a recent decline of 4.67% and a market capitalization of 14.472 billion yuan. The company is positioned in the optical communication and data center sectors, benefiting from advancements in optical chip integration and 5G technology [1][4]. Company Overview - Wuhan LianTe Technology was established on October 28, 2011, and went public on September 13, 2022. The company specializes in the research, development, production, and sales of optical communication transceiver modules. Its revenue composition includes 92.72% from optical modules of 10G and above, 5.57% from below 10G modules, and 1.71% from material sales and leasing [7]. Market Position and Technology - The company has developed core capabilities in optical chip integration, high-speed optical devices, and high-speed optical module design and production. It is currently working on 800G optical modules and technologies required for next-generation products, including NPO and CPO [2][3]. - The primary application markets for the company's optical modules include data communication, telecommunications, and emerging markets, with the data communication market being the fastest-growing segment [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 847 million yuan, representing a year-on-year growth of 31.75%. The net profit attributable to the parent company was 81.796 million yuan, also reflecting a growth of 31.39% [8]. - As of September 30, 2025, the company had a shareholder base of 24,900, with an increase of 7.14% from the previous period [8]. International Exposure - The company benefits from a significant international revenue share, with 89.07% of its revenue coming from overseas markets, positively impacted by the depreciation of the Chinese yuan [3]. Investment and Shareholder Dynamics - The company has distributed a total of 46.852 million yuan in dividends since its A-share listing. The top ten circulating shareholders include significant institutional investors, indicating a diverse ownership structure [9].

来源：新浪证券-红岸工作室 1、公司办公地址：广东省珠海市香洲区高新区唐家湾镇金园一路8号厂房。 2、2023年7月27日互动易回复：公司子公司捷锐科技主要业务是非标自动化产线和设备方面的设计、开 发、安装和调试，其中包括机器人应用程序和软件设计开发，通过对客户应用场景的研究开发，为客户 提供智能化生产解决方案。 3、2023年7月19日互动易回复：公司子公司捷锐科技联合研发的人工智能柔性抓取设备主要是基于3D 视觉、AI深度学习等技术对工件进行识别、引导抓取，主要针对小批量、多品种产品在自动化生产中 快速换料的需求；集成的AGV智能物流线，主要运用于在生产过程物料的运输，具有高度的智能化和 自动化，通过其控制系统进行调度管理，有效提高系统灵活性和生产效率。 4、2023年7月19号互动易显示：公司的主营业务是计算机外设领域，主要从事键盘、鼠标等计算机外设 产品的研发、生产及销售。公司可以为智能家居中涉及鼠标、键盘等计算机外设产品提供支持。 5、根据2024年年报，公司海外营收占比为87.24%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今 ...

Core Viewpoint - The company, Zhonghong Medical, is experiencing a decline in stock price and has a significant portion of its revenue coming from overseas sales, benefiting from the depreciation of the RMB. The company is involved in the development of innovative medical products and has a strong focus on export-oriented ODM production. Group 1: Company Overview - Zhonghong Medical is primarily engaged in the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves for medical and industrial use [9] - The company was established on December 22, 2010, and went public on April 27, 2021 [9] - As of September 30, the company had 22,400 shareholders, with an average of 17,531 circulating shares per person, a decrease of 10.11% from the previous period [10] Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38% [10] - The net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10] - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed in the last three years [11] Group 3: Market Position and Trends - The company’s overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4] - Zhonghong Medical is classified as a state-owned enterprise, with its ultimate controller being the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal Government [5] - The company is involved in various sectors, including nuclear pollution prevention, pet economy, and medical device concepts [2]

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.70% on November 20, with a trading volume of 1.11 billion yuan and a market capitalization of 3.242 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2] - As of October 31, the number of shareholders in Canar Medical was 7,857, an increase of 4.11% from the previous period, with an average of 9,627 circulating shares per person, a decrease of 3.95% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - The company benefits from a high overseas revenue ratio, with 90.61% of its revenue coming from international markets, positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.92 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6] - The stock is approaching a resistance level of 27.05 yuan, indicating potential for a pullback unless this level is breached, which could trigger an upward trend [6]

来源：新浪证券-红岸工作室 11月20日，药明康德涨0.50%，成交额23.12亿元，换手率0.99%，总市值2794.89亿元。 异动分析 CRO概念+创新药+人民币贬值受益 1、公司是国际领先的开放式能力与技术平台,为全球生物医药行业提供全方位、一体化的新药研发和生 产服务。 2、国内医药外包行业龙头,是国内最早开始从事医药研发生产外包的CRO和CMO一体化公司,高层管理 团队共拥有超过200项的已授权和申请中的专利成果;其主营业务为小分子化学药的发现、研发及生产的 全方位、一体化平台服务,以全产业链平台的形式面向全球制药企业提供各类新药的研发、生产及配套 服务;公司还在境外提供医疗器械检测及境外精准医疗研发生产服务。 3、根据2024年年报，公司海外营收占比为78.67%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入3320.88万，占比0.01%，行业排名1/51，连续2日被主力资金增仓；所属行业主力净流 入-10.45亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入3320.88万-4.24 ...

来源：新浪证券-红岸工作室 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-459.02万，占比0.12%，行业排名84/132，连续3日被主力资金减仓；所属行业主力净流 入-11.41亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-459.02万-1002.64万-1083.34万-721.59万-5530.67万 11月20日，海泰新光跌1.97%，成交额3710.52万元，换手率0.66%，总市值55.36亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞 ...